144 - CG Oncology, Inc. (0001991792) (Subject)

144 - CG Oncology, Inc. (0001991792) (Subject)

10-Q - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

10-Q - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

10-K - CG Oncology, Inc. (0001991792) (Filer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4/A - CG Oncology, Inc. (0001991792) (Issuer)

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing –  IRVINE, Calif., Aug. 08, 2024 (GLOBE NE

IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing. "Bladder cancer is a highly recurrent disease with few treatment options a

– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine and featured at ASCO 2024 – – 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint of the phase 2 study – IRVINE, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the publication in Nature Medicine of final results from the Company's CORE-001 Phase 2 trial of cretostimogene plus pembrolizumab in BCG-unres

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL. "There is a signifi

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-Risk NMIBC (IR-NMIBC)Final Results from CORE-001 Phase 2 Clinical Trial of Cretostimogene in Combination with Pembrolizumab in BCG-Unresponsive HR-NMIBC will be presented at ASCO 2024 Completed Oversubscribed and Upsized $437 Million Initial Public Offering that Extends Expected Runway Through 2027 IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical b

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT. The executive leadership team will provide updates on the company's progress, following an oral presentation of its oncolytic immunotherapy cretostimogene at the American Urological Association (AUA) Annual Meeting in San Antonio, TX. CG Oncology will broadcast the presentations live on the company's investor relations website, https://ir.cgoncology.com, where a w

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL. "We are delighted to be sharing the final results from our CORE-001 Phase 2 trial at ASCO, in line

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association (AUA) Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024. CG Oncology is exhibiting at the AUA meeting at booth #100. "We are excited to share encouraging 12-month Phase 3 monotherapy results from the BOND-003 study at AUA 2024," said Ambaw Bellete, President and

SC 13G - CG Oncology, Inc. (0001991792) (Subject)

SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

SC 13G - CG Oncology, Inc. (0001991792) (Subject)

UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00

RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00

ROTH MKM initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00

BofA Securities initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00

Cantor Fitzgerald initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $75.00

Goldman initiated coverage of CG Oncology with a rating of Neutral and set a new price target of $42.00

Morgan Stanley initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00